Login to Your Account


FDA to look at price comparisons in Rx advertising

By Mari Serebrov
Washington Editor

Wednesday, May 7, 2014

Anticipating a day when price comparisons may be a key element in prescription drug advertising, the FDA plans to study how best to present price information in physician and direct-to-consumer (DTC) ads without implying that two drugs are interchangeable. The results of the studies could dictate how drugmakers market biosimilars in the U.S.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription